SCHEMBL13219620

SCHEMBL13219620

Cc1cnc(O)c2cnccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.40
KAT2B Q92831 1/20 0.40
KAT8 Q9H7Z6 1/20 0.40
HIPK2 Q9H2X6 1/20 0.39
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 1/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPKAPK2 P49137 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
SIRT3 Q9NTG7 1/20 0.36
PLAU P00749 1/20 0.36
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KIT P10721 2/20 0.35
HPGD P15428 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
GMNN O75496 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18266939 0.79 HIPK2 (0.37) EP300KAT2BKAT8HIPK2ADORA3
SCHEMBL5398756 0.77 PLAU (0.52) KDM4ETDP1PLAUALDH1A1SMN1; SMN2
SCHEMBL27752552 0.76 EP300 (0.40) EP300KAT2BKAT8ADORA3KDM4E
SCHEMBL17068258 0.76 TBK1 (0.46) EP300KAT2BKAT8HIPK2TDP1
SCHEMBL3028548 0.76 EP300 (0.53) EP300KAT2BKAT8KDM4EMAPKAPK2
SCHEMBL18266941 0.75 CCR1 (0.35) EP300KAT2BKAT8HIPK2ADORA3
SCHEMBL812489 0.73 CYP1A2 (0.46) EP300KAT2BKAT8HIPK2ADORA3
SCHEMBL11293218 0.72 EP300 (0.40) EP300KAT2BKAT8HIPK2ADORA3
SCHEMBL3690210 0.72 EP300 (0.47) EP300KAT2BKAT8ADORA3ADORA2A
SCHEMBL8958018 0.71 MAPK10 (0.43) EP300KAT2BKAT8ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2010-08-12 US disclosed
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2009-04-30 US disclosed
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B EP300 1568/4885KAT2B 3116/4885KAT8 3560/4885
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B EP300 1568/4885KAT2B 3116/4885KAT8 3560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.